A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 11, 2005

Primary Completion Date

December 17, 2008

Study Completion Date

April 26, 2023

Conditions

Ovarian NeoplasmsBRCA1 ProteinBRCA2 Protein

Interventions

DRUG

KU-0059436 (AZD2281)(PARP inhibitor)

oral

Trial Locations (5)

Research Site, Brussels

Research Site, Amsterdam

Research Site, Szczecin

Research Site, Edinburgh

Research Site, London